News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Edward D. Esplin: Clinician Responses to Germline Genetic Testing in Prostate Cancer Management
Photo from Edward D. Esplin/X
Aug 31, 2024, 11:09

Edward D. Esplin: Clinician Responses to Germline Genetic Testing in Prostate Cancer Management

Edward D. Esplin, Clinical Geneticist at Invitae, shared on X:

“Up to 17% of prostate cancer patients have PGVs with germline testing

36% of universally tested PC patients had positive health outcomes 2/2 genetic testing results

Shore et al.

‘This study supports universal germline genetic testing for patients with prostate cancer, and it demonstrates the clinical utility of germline genetic testing results—both positive and negative—for…the care of patients and their families.’”

Edward D. Esplin: Clinician Responses to Germline Genetic Testing in Prostate Cancer Management

Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer

Edward D. Esplin

Authors: Neal Shore, Christopher Pieczonka, Sean Heron, Mukaram Gazi, David Cahn, Laurence H. Belkoff, Aaron Berger, Brian Mazzarella, Joseph Veys, Charles Idom, David Morris, Gautam Jayram, Alexander Engelman, Paul Dato, Richard Bevan-Thomas, David R. Wise, Mary Kay Hardwick, Susan Rojahn, Paige Layman, Brandie Heald, Rachel E. Ellsworth, Kathryn E. Hatchell, Robert L. Nussbaum, Sarah M. Nielsen, Edward D. Esplin

Source: Edward D. Esplin/X

 

Aaron Berger Alexander Engelman Brandie Heald Brian Mazzarella cancer Charles Idom Christopher Pieczonka David Cahn David Morris David R. Wise Edward D. Esplin Gautam Jayram germline genetic testing Joseph Veys Kathryn E. Hatchell Laurence H. Belkoff Mary Kay Hardwick Mukaram Gazi Neal Shore OncoDaily Oncology Paige Layman Paul Dato prostate cancer Rachel E. Ellsworth Richard Bevan-Thomas Robert L. Nussbaum Sarah M. Nielsen Sean Heron Susan Rojahn
Special Coverage
Blog
Nov 13, 2024, 11:01
LGCW2024 session on Galvanising African cancer research building a strong cancer workforce - AORTIC- Africa
Blog
Nov 13, 2024, 10:59
Bernard Fox received SITC lifetime achievement award
Blog
Nov 13, 2024, 10:54
Hear Her campaign Increasing awareness about lung cancer in women
Blog
Nov 13, 2024, 10:52
Johnson & Johnson Seeks Approval for DARZALEX FASPRO as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma
Blog
Nov 13, 2024, 10:47
FDA approves obecabtagene autoleucel for relapsed or refractory B-cell precursor ALL
Blog
Nov 13, 2024, 10:45
OncoInfluencers to Follow on Social Media: Dr. Nitin Jain
Insight
Nov 13, 2024, 10:37
UCLA: Combination approach shows promise for treating rare, aggressive cancers
Opinion
Nov 13, 2024, 10:32
The 6th Biennial Miami Epigenetics and Cancer Symposium to be held in Sylvester Comprehensive Cancer Center
Blog
Nov 13, 2024, 10:16
Highlights from IU Simon Comprehensive Cancer Center’s End Lung Cancer Now Gathering - Hoosier Cancer Research Network
Blog
Nov 13, 2024, 10:06
A first-in-class Antibody Drug Conjugate that works by directly stimulating the immune system
Blog
Nov 13, 2024, 09:55
Moderna Incorporation announced the awardees of its 2024 Australia Fellowship Program
Blog
Nov 13, 2024, 09:39
AI tools to improve diagnosis and therapy in neuro-oncology